The company has not filed an annual or quarterly report since its FY2020 10-K, filed Mar 29, 2021. Its latest SEC filing is a SCHEDULE 13G from Aug 13, 2026.
10-K for FY2020, filed Mar 29, 2021
The sections below describe the company as of the FY2020 annual report.
Provides loans to healthcare companies and collects royalties from product sales and patents covering antibody humanization.
10-K for FY2020, filed Mar 29, 2021The income generating assets included in continuing operations consist of (i) notes and other long-term receivables, (ii) equity…View ↗
We have entered into credit agreements with borrowers across the healthcare industry, under which we made available cash loans to be used…View ↗
Our Income Generating Assets segment consisted of revenue derived from (i) notes and other long-term receivables, (ii) royalty rights and…View ↗
Earns income from loans to healthcare borrowers and royalty rights tied to product sales; the CareView loan agreement called for quarterly interest payments.
10-K for FY2020, filed Mar 29, 2021 10-K for FY2017, filed Mar 16, 2018
$30.7M
10-K for FY2020, filed Mar 27, 2021
$30.7M ↗No. It lost $70.4M in FY2019.
Shrank. Revenue fell 95% in 4 years, from $590.4M in FY2015 to $30.7M in FY2019, about 52% a year.
From investing to winding down
The older business description focused on building a portfolio through loans, royalty deals and commercial product acquisitions. The latest report instead describes monetizing assets, pursuing liquidation and distributing proceeds to stockholders.
10-K for FY2017, filed Mar 16, 2018 10-K for FY2020, filed Mar 29, 2021
Loading...
